ijms-logo

Journal Browser

Journal Browser

Peroxisome and Lysosome in Health and Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 4583

Special Issue Editor

Equipe 5, Neurobiologie des Comportements Alimentaires/Neurobiology of Feeding Behaviours 9E, Boulevard Jeanne d'Arc, 21000 Dijon, France
Interests: oxysterols; very-long-chain fatty acids; lipid metabolism; diet; peroxisomes; biotherapies; inflammation; cancer; cell cycle and apoptosis; autophagy; biological membranes; oxidative damage; biomarkers; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to peroxisomes and lysosomes, identified by C. De Duve.

Peroxisomes are genome-free intracellular organelles performing essential metabolic functions: beta-oxidation of very long-chain fatty acids, catabolism of prostaglandins and polyamines, first reactions in the biogenesis of plasmalogens (e.g., PAF-acetate) and bile salts, degradation of H202 , etc. There are many peroxisomal diseases, e.g., genetic disorders, which affect peroxisome formation or impair a single enzymatic or transport function. With the exception of X-linked adrenoleukodystrophy, these diseases are transmitted in an autosomal recessive manner. Their presentation is heterogeneous, with neonatal, infantile, and adult forms. In recent years, peroxisomes have also been implicated in immunity.

Lysosomes, small spherical structures delimited by a lipid membrane and located in the cytoplasm of eukaryotic cells, are cellular organelles whose hydrolytic enzymes play an essential role in the degradation of intracellular molecules and organelles (autophagy) and in the destruction of molecules ingested by the cell (heterophagy). They are the site of two pathologies, one non-specific, which occurs following any hepatic damage, the other specific, hereditary, which depends on the structure of the lysosome itself, in particular its enzymatic equipment. The term “lysosomal diseases” covers around fifty disabling conditions in children and adults, all of which have one thing in common: a genetic defect that causes the lysosome to malfunction. The lysosome no longer performs its function of recycling and eliminating waste. Metabolites gradually accumulate in the cells and, consequently, in the tissues of the body of the sick child or adult, disrupting their functioning. This accumulation leads to the appearance of lesions in various organs, including the bones, heart, lungs, liver, spleen, and brain, causing particularly serious and irreversible disorders.

These pathologies, whether peroxisomal or lysosomal, have few treatments available. We therefore need to know more about these organelles and their functions in order to better understand the pathophysiology of their associated diseases and thus identify possible new treatments.

Dr. Anne Vejux
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peroxisomes
  • lysosomes
  • autophagy
  • lysosomal diseases
  • peroxidase
  • oxidative stress
  • acid hydrolase
  • lysosomal storage disease(LSD)
  • gaucher disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 4628 KiB  
Article
Disruption of Man-6-P-Dependent Sorting to Lysosomes Confers IGF1R-Mediated Apoptosis Resistance
by Asena Aynaci, Maxence Toussaint, Florentine Gilis, Martine Albert, Jean-François Gaussin, Michel Jadot and Marielle Boonen
Int. J. Mol. Sci. 2025, 26(8), 3586; https://doi.org/10.3390/ijms26083586 - 10 Apr 2025
Viewed by 416
Abstract
Mutations in GNPTAB underlie mucolipidosis II and mucolipidosis III α/β, which are inherited lysosomal storage disorders caused by a defective UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine phosphotransferase. As a result, newly synthesized acid hydrolases fail to acquire Mannose-6-Phosphate (Man-6-P) sorting signals, or do so to a lesser [...] Read more.
Mutations in GNPTAB underlie mucolipidosis II and mucolipidosis III α/β, which are inherited lysosomal storage disorders caused by a defective UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine phosphotransferase. As a result, newly synthesized acid hydrolases fail to acquire Mannose-6-Phosphate (Man-6-P) sorting signals, or do so to a lesser extent, and exhibit an impaired trafficking to lysosomes. Interestingly, we found that GNPTAB knockout HeLa cells are resistant to several cytotoxic agents: doxorubicin, chloroquine, staurosporine and paclitaxel. While we detected an increased trapping of weak bases in the expanded lysosomal population of these cells, which could reduce the effect of doxorubicin and chloroquine; the decreased cell response to staurosporine and paclitaxel suggested the involvement of alternative resistance mechanisms. Indeed, further investigation revealed that the hyperactivation of the Insulin-like Growth Factor 1 Receptor (IGF1R) pathway is a central player in the apoptosis resistance exhibited by Man-6-P sorting deficient cells. Full article
(This article belongs to the Special Issue Peroxisome and Lysosome in Health and Disease)
Show Figures

Figure 1

16 pages, 1613 KiB  
Article
mRNA Degradation as a Therapeutic Solution for Mucopolysaccharidosis Type IIIC: Use of Antisense Oligonucleotides to Promote Downregulation of Heparan Sulfate Synthesis
by Juliana Inês Santos, Mariana Gonçalves, Matilde Barbosa Almeida, Hugo Rocha, Ana Joana Duarte, Liliana Matos, Luciana Vaz Moreira, Marisa Encarnação, Paulo Gaspar, Maria João Prata, Maria Francisca Coutinho and Sandra Alves
Int. J. Mol. Sci. 2025, 26(3), 1273; https://doi.org/10.3390/ijms26031273 - 1 Feb 2025
Viewed by 1049
Abstract
Mucopolysaccharidosis type IIIC is a neurodegenerative lysosomal storage disorder (LSD) characterized by the accumulation of undegraded heparan sulfate (HS) due to the lack of an enzyme responsible for its degradation: acetyl-CoA:α-glucosaminide N-acetyltransferase (HGSNAT). Classical treatments are ineffective. Here, we attempt a new approach [...] Read more.
Mucopolysaccharidosis type IIIC is a neurodegenerative lysosomal storage disorder (LSD) characterized by the accumulation of undegraded heparan sulfate (HS) due to the lack of an enzyme responsible for its degradation: acetyl-CoA:α-glucosaminide N-acetyltransferase (HGSNAT). Classical treatments are ineffective. Here, we attempt a new approach in genetic medicine, genetic substrate reduction therapy (gSRT), to counteract this neurological disorder. Briefly, we used synthetic oligonucleotides, particularly gapmer antisense oligonucleotides (ASOs), to target the synthesis of the accumulated compounds at the molecular level, downregulating a specific gene involved in the first step of HS biosynthesis, XYLT1. Our goal was to reduce HS production and, consequently, its accumulation. Initially, five gapmer ASOs were designed and their potential to decrease XYLT1 mRNA levels were tested in patient-derived fibroblasts. Subsequent analyses focused on the two best performing molecules alone. The results showed a high inhibition of the XYLT1 gene mRNA (around 90%), a decrease in xylosyltransferase I (XT-I) protein levels and a reduction in HS storage 6 and 10 days after transfection (up to 21% and 32%, respectively). Overall, our results are highly promising and may represent the initial step towards the development of a potential therapeutic option not only for MPS IIIC, but virtually for every other MPS III form. Ultimately, the same principle may also apply to other neuropathic MPS. Full article
(This article belongs to the Special Issue Peroxisome and Lysosome in Health and Disease)
Show Figures

Figure 1

13 pages, 4334 KiB  
Article
Limited Alleviation of Lysosomal Acid Lipase Deficiency by Deletion of Matrix Metalloproteinase 12
by Martin Buerger, Melina Amor, Alena Akhmetshina, Valentina Bianco, Bianca Perfler, Armin Zebisch, Thomas Weichhart and Dagmar Kratky
Int. J. Mol. Sci. 2024, 25(20), 11001; https://doi.org/10.3390/ijms252011001 - 13 Oct 2024
Viewed by 2549
Abstract
Lysosomal acid lipase (LAL) is the only known enzyme that degrades cholesteryl esters and triglycerides at an acidic pH. In LAL deficiency (LAL-D), dysregulated expression of matrix metalloproteinase 12 (MMP-12) has been described. The overexpression of MMP-12 in myeloid lineage cells causes an [...] Read more.
Lysosomal acid lipase (LAL) is the only known enzyme that degrades cholesteryl esters and triglycerides at an acidic pH. In LAL deficiency (LAL-D), dysregulated expression of matrix metalloproteinase 12 (MMP-12) has been described. The overexpression of MMP-12 in myeloid lineage cells causes an immune cell dysfunction resembling that of Lal knockout (Lal KO) mice. Both models develop progressive lymphocyte dysfunction and expansion of myeloid-derived suppressor (CD11b+ Gr-1+) cells. To study whether MMP-12 might be a detrimental contributor to the pathology of LAL-D, we have generated Lal/Mmp12 double knockout (DKO) mice. The phenotype of Lal/Mmp12 DKO mice closely resembled that of Lal KO mice, while the weight and morphology of the thymus were improved in Lal/Mmp12 DKO mice. Cytological examination of blood smears showed a mildly reversed lymphoid-to-myeloid shift in DKO mice. Despite significant decreases in CD11b+ Ly6G+ cells in the peripheral blood, bone marrow, and spleen of Lal/Mmp12 DKO mice, the hematopoietic bone marrow progenitor compartment and markers for neutrophil chemotaxis were unchanged. Since the overall severity of LAL-D remains unaffected by the deletion of Mmp12, we conclude that MMP-12 does not represent a viable target for treating the inflammatory pathology in LAL-D. Full article
(This article belongs to the Special Issue Peroxisome and Lysosome in Health and Disease)
Show Figures

Figure 1

Back to TopTop